Racial disparities in Black men with prostate cancer: A literature review.
Racial disparities in Black men with prostate cancer: A literature review.
复制标题
DOI：
10.1002/cncr.34433
复制
发表时间：
2022-11-01
期刊：
影响因子：
6.2
通讯作者：
George, Daniel J.
中科院分区：
文献类型：
--
作者：
Lillard, James W., Jr.;Moses, Kelvin A.;Mahal, Brandon A.;George, Daniel J.
关键词：
与白色男性相比，黑人男性受前列腺癌（PCa）的影响不成比例，表现更早，疾病更具侵袭性，死亡率更高。此外，黑人男子获得前列腺癌治疗的机会较少，诊断和治疗之间的延迟时间较长。在这篇综述中，作者讨论了导致种族差异的因素，并提出了改善获得护理和增加PCa黑人男性临床试验参与的解决方案。在患有PCa的黑人男性中观察到的种族差异是多方面的，从制度性种族主义演变而来。文化因素包括对医疗保健系统的普遍不信任，医患沟通不畅，缺乏关于PCa和治疗方案的信息，对PCa诊断的恐惧以及对疾病的社会耻辱感。在美国，种族差异的地理趋势已经被观察到。经济因素，例如，护理费用、恢复时间和癌症债务在PCa治疗和结果中观察到的种族差异中起着重要作用。在基因组和精准医学研究中，种族多样性往往缺乏。黑人男性在关键的3期PCa试验中的代表性很低，由于缺乏认识，临床试验研究团队缺乏多样性以及医疗保健提供者推荐临床研究的偏见，他们可能不太愿意参加临床试验。作者提出了解决这些因素的解决方案，包括教育临床医生和机构了解黑人男性所经历的障碍，增加医疗保健提供者和临床研究团队的多样性，并使黑人男性能够参与他们的治疗，这是为PCa黑人男性创造公平的关键。前列腺癌对黑人男性的负面影响大于其他种族的男性。医疗保健系统中的隔离和虐待历史可能会导致黑人之间的不信任。黑人男性的结果更糟，因为他们不太可能接受前列腺癌的筛查或治疗。黑人男性也不太可能参与临床研究，这使得研究人员很难了解黑人男性如何受到前列腺癌的影响。解决这些差异的建议包括教授医生和护士关于黑人男性接受治疗的问题，以及改善黑人男性获得前列腺癌信息的方式。前列腺癌诊断，治疗和结果中的种族差异是多方面的，并从制度性种族主义演变而来。这些差异可以通过教育医生了解黑人男性接受医疗保健所面临的障碍，确定传达治疗和临床试验信息的最佳做法，以及增加医疗保健专业人员的多样性来解决。
Black men are disproportionately affected by prostate cancer (PCa), with earlier presentation, more aggressive disease, and higher mortality rates versus White men. Furthermore, Black men have less access to PCa treatment and experience longer delays between diagnosis and treatment. In this review, the authors discuss the factors contributing to racial disparities and present solutions to improve access to care and increase clinical trial participation among Black men with PCa. Racial disparities observed among Black men with PCa are multifaceted, evolving from institutional racism. Cultural factors include generalized mistrust of the health care system, poor physician‐patient communication, lack of information on PCa and treatment options, fear of PCa diagnosis, and perceived societal stigma of the disease. In the United States, geographic trends in racial disparities have been observed. Economic factors, e.g., cost of care, recovery time, and cancer debt, play an important role in racial disparities observed in PCa treatment and outcomes. Racial diversity is often lacking in genomic and precision medicine studies. Black men are largely underrepresented in key phase 3 PCa trials and may be less willing to enroll in clinical trials due to lack of awareness, lack of diversity in clinical trial research teams, and bias of health care providers to recommend clinical research. The authors propose solutions to address these factors that include educating clinicians and institutions on the barriers Black men experience, increasing the diversity of health care providers and clinical research teams, and empowering Black men to be involved in their treatment, which are keys to creating equity for Black men with PCa. Prostate cancer negatively affects Black men more than men of other races. The history of segregation and mistreatment in the health care system may contribute to mistrust among Black men. Outcomes are worse for Black men because they are less likely to be screened or to receive treatment for prostate cancer. Black men also are unlikely to participate in clinical research, making it difficult for investigators to understand how Black men are affected by prostate cancer. Suggestions for addressing these differences include teaching physicians and nurses about the issues Black men experience getting treatment and improving how Black men get information on prostate cancer. Racial disparities seen within prostate cancer diagnosis, treatment, and outcomes are multifaceted and evolve from institutional racism. The disparities can be addressed by educating physicians about the barriers faced by Black men receiving health care, identifying the best practices for conveying information on treatments and clinical trials, and increasing diversity among health care professionals.
登录
查看更多内容
DOI：
10.1177/1557988318784838
发表时间：
2018-11
期刊：
American journal of men's health
影响因子：
--
作者：
Hewitt T;Killinger KA;Hiller S;Boura JA;Lutz M
通讯作者：
Lutz M
影响因子：
2.8
作者：
Baffoe-Bonnie, Agnes B.;Kittles, Rick A.;Carpten, John D.
通讯作者：
Carpten, John D.
影响因子：
3.7
作者：
Hastert, Theresa A.;Banegas, Matthew P.;Schwartz, Ann G.
通讯作者：
Schwartz, Ann G.
影响因子：
1.6
作者：
Bieber, Christiane;Nicolai, Jennifer;Eich, Wolfgang
通讯作者：
Eich, Wolfgang
DOI：
10.1016/j.urolonc.2018.12.004
发表时间：
2019-04-01
影响因子：
2.7
作者：
Everist, Mary M.;Howard, Lauren E.;Freedland, Stephen J.
通讯作者：
Freedland, Stephen J.